Matches in SemOpenAlex for { <https://semopenalex.org/work/W152037462> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W152037462 endingPage "907" @default.
- W152037462 startingPage "899" @default.
- W152037462 abstract "With the improvements in first- and second-line treatments in non-small cell lung cancer (NSCLC), there is an increasing number of patients who receive third-line therapy. No other standard choice for third-line therapy aside from erlotinib is possible. This study investigated the efficacy and safety of single-agent chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), doublet chemotherapy and chemo-targeted therapy as third-line treatment in advanced NSCLC.This study included 233 stage IIIb or IV NSCLC patients who were retrospectively reviewed to explore the differences in survival between different treatments.The median progression free survival (PFS) in the EGFR-TKIs, single-agent, doublet and chemo-targeted groups was 3.83, 2.72, 2.86 and 3.29 months, respectively (p = 0.073). The median OS from the initiation of the third-line treatment was 11.16, 8.24, 8.49 and 9.33 months in the 4 groups (p=0.02). The rates of grade IIIIV toxicities were 16.4, 27.6, 57.3 and 44.0% ( p <0.001), respectively with the third-line treatment, and overall survival (OS) was prolonged in patients who never smoked (p=0.040), had adenocarcinoma (p=0.034), had good ECOG performance status (PS) (p=0.012) and achieved disease control after both first-and second-line treatments (p =0.031).Patients with advanced NSCLC who never smoked, had adenocarcinoma, have good PS, and good disease control from the first- and second-line therapies could benefit more with third-line treatment. EGFR-TKIs and chemo-targeted therapy showed increased OS compared with single-agent and doublet chemotherapy." @default.
- W152037462 created "2016-06-24" @default.
- W152037462 creator A5024447849 @default.
- W152037462 creator A5032412515 @default.
- W152037462 creator A5049194580 @default.
- W152037462 creator A5059746697 @default.
- W152037462 creator A5060002817 @default.
- W152037462 creator A5083529934 @default.
- W152037462 creator A5085632651 @default.
- W152037462 creator A5091255410 @default.
- W152037462 date "2013-12-18" @default.
- W152037462 modified "2023-09-27" @default.
- W152037462 title "Third-line therapy in advanced non-small cell lung cancer." @default.
- W152037462 cites W1968626722 @default.
- W152037462 cites W1981599526 @default.
- W152037462 cites W1998340100 @default.
- W152037462 cites W2033801862 @default.
- W152037462 cites W2059103130 @default.
- W152037462 cites W2084431608 @default.
- W152037462 cites W2100639702 @default.
- W152037462 cites W2101995865 @default.
- W152037462 cites W2138297714 @default.
- W152037462 cites W2139248078 @default.
- W152037462 cites W2140830955 @default.
- W152037462 cites W2145835533 @default.
- W152037462 cites W2153477391 @default.
- W152037462 cites W2153886286 @default.
- W152037462 cites W2169436143 @default.
- W152037462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24344015" @default.
- W152037462 hasPublicationYear "2013" @default.
- W152037462 type Work @default.
- W152037462 sameAs 152037462 @default.
- W152037462 citedByCount "7" @default.
- W152037462 countsByYear W1520374622015 @default.
- W152037462 countsByYear W1520374622016 @default.
- W152037462 countsByYear W1520374622017 @default.
- W152037462 countsByYear W1520374622018 @default.
- W152037462 countsByYear W1520374622022 @default.
- W152037462 crossrefType "journal-article" @default.
- W152037462 hasAuthorship W152037462A5024447849 @default.
- W152037462 hasAuthorship W152037462A5032412515 @default.
- W152037462 hasAuthorship W152037462A5049194580 @default.
- W152037462 hasAuthorship W152037462A5059746697 @default.
- W152037462 hasAuthorship W152037462A5060002817 @default.
- W152037462 hasAuthorship W152037462A5083529934 @default.
- W152037462 hasAuthorship W152037462A5085632651 @default.
- W152037462 hasAuthorship W152037462A5091255410 @default.
- W152037462 hasConcept C121608353 @default.
- W152037462 hasConcept C126322002 @default.
- W152037462 hasConcept C143998085 @default.
- W152037462 hasConcept C2776256026 @default.
- W152037462 hasConcept C2776694085 @default.
- W152037462 hasConcept C2776907518 @default.
- W152037462 hasConcept C2778087573 @default.
- W152037462 hasConcept C2779438470 @default.
- W152037462 hasConcept C2780739268 @default.
- W152037462 hasConcept C2781182431 @default.
- W152037462 hasConcept C71924100 @default.
- W152037462 hasConceptScore W152037462C121608353 @default.
- W152037462 hasConceptScore W152037462C126322002 @default.
- W152037462 hasConceptScore W152037462C143998085 @default.
- W152037462 hasConceptScore W152037462C2776256026 @default.
- W152037462 hasConceptScore W152037462C2776694085 @default.
- W152037462 hasConceptScore W152037462C2776907518 @default.
- W152037462 hasConceptScore W152037462C2778087573 @default.
- W152037462 hasConceptScore W152037462C2779438470 @default.
- W152037462 hasConceptScore W152037462C2780739268 @default.
- W152037462 hasConceptScore W152037462C2781182431 @default.
- W152037462 hasConceptScore W152037462C71924100 @default.
- W152037462 hasIssue "4" @default.
- W152037462 hasLocation W1520374621 @default.
- W152037462 hasOpenAccess W152037462 @default.
- W152037462 hasPrimaryLocation W1520374621 @default.
- W152037462 hasRelatedWork W2069371231 @default.
- W152037462 hasRelatedWork W2186047679 @default.
- W152037462 hasRelatedWork W2304969394 @default.
- W152037462 hasRelatedWork W2345394748 @default.
- W152037462 hasRelatedWork W2346455687 @default.
- W152037462 hasRelatedWork W2508468768 @default.
- W152037462 hasRelatedWork W2744426316 @default.
- W152037462 hasRelatedWork W2801303484 @default.
- W152037462 hasRelatedWork W2888534976 @default.
- W152037462 hasRelatedWork W4229008161 @default.
- W152037462 hasVolume "18" @default.
- W152037462 isParatext "false" @default.
- W152037462 isRetracted "false" @default.
- W152037462 magId "152037462" @default.
- W152037462 workType "article" @default.